203 - References

References

206 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 References

1. Dzahini O, et al. Antipsychotic drug use and pneumonia: systematic review and meta-­analysis. J Psychopharmacol 2018; 32:1167–1181.
2. Cepaityte D, et al. Exploring a safety signal of antipsychotic-­associated pneumonia: a pharmacovigilance–pharmacodynamic study. Schizophr Bull 2020; 47:672–681.
3. Luykx JJ, et al. Pneumonia risk, antipsychotic dosing, and anticholinergic burden in schizophrenia. JAMA Psychiatry 2024; 81:967–975.
4. Rohde C, et al. Antipsychotic medication exposure, clozapine, and pneumonia: results from a self-­controlled study. Acta Psychiatr Scand 2020; 142:78–86.
5. Chan HY, et al. Is antipsychotic treatment associated with risk of pneumonia in people with serious mental illness? The roles of severity of psychiatric symptoms and global functioning. J Clin Psychopharmacol 2019; 39:434–440.
6. Chen YH, et al. Poor clinical outcomes among pneumonia patients with schizophrenia. Schizophr Bull 2011; 37:1088–1094.
7. Nose M, et  al. Antipsychotic drug exposure and risk of pneumonia: a systematic review and meta-­analysis of observational studies. Pharmacoepidemiol Drug Saf 2015; 24:812–820.
8. Tolppanen AM, et al. Antipsychotic use and risk of hospitalization or death due to pneumonia in persons with and those without Alzheimer disease. Chest 2016; 150:1233–1241.
9. Cepaityte D, et al. Exploring a safety signal of antipsychotic-­associated pneumonia: a pharmacovigilance-­pharmacodynamic study. Schizophr Bull 2021; 47:672–681.
10. Chen YH, et al. Analysis of risk factors for hospital-­acquired pneumonia in schizophrenia. Front Psychiatry 2024; 15:1414332.
11. Kuo CJ, et al. Second-­generation antipsychotic medications and risk of pneumonia in schizophrenia. Schizophr Bull 2013; 39:648–657.
12. Yang SY, et al. Antipsychotic drugs, mood stabilizers, and risk of pneumonia in bipolar disorder: a nationwide case-­control study. J Clin Psychiatry 2013; 74:e79–e86.
13. Trifiro G, et al. Association of community-­acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-­control study. Ann Intern Med 2010; 152:418–440.
14. Kang N, et al. Association between initial clozapine titration and pneumonia risk among patients with schizophrenia in a Korean tertiary hospital. Schizophr Res 2024; 268:107–113.
15. Cheng SY, et al. Benzodiazepines and risk of pneumonia in schizophrenia: a nationwide case-­control study. Psychopharmacology (Berl) 2018; 235:3329–3338.
16. Partanen JJ, et al. High burden of ileus and pneumonia in clozapine-­treated individuals with schizophrenia: a Finnish 25-­year follow-­up register study. Am J Psychiatry 2024; 181:879–892.
17. Schoretsanitis G, et  al. An update on the complex relationship between clozapine and pneumonia. Expert Rev Clin Pharmacol 2021; 14:145–149.
18. Villasante-­Tezanos AG, et al. Pneumonia risk: approximately one-­third is due to clozapine and two-­thirds is due to treatment-­resistant schizophrenia. Acta Psychiatr Scand 2020; 142:66–67.
19. Hung GC, et al. Antipsychotic reexposure and recurrent pneumonia in schizophrenia: a nested case-­control study. J Clin Psychiatry 2016; 77:60–66.
20. Mace S, et al. Incident infection during the first year of treatment: a comparison of clozapine and paliperidone palmitate long-­acting injection. J Psychopharmacol 2022; 36:232–237.
21. de Leon J, et al. Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-­generation antipsychotics. World Psychiatry 2020; 19:120–121.